Participation of the BPRC in a new consortium for the development of an AIDS vaccine
2 February 2016
Although there has been enormous progress in the prevention and treatment of HIV/AIDS, worldwide still 35 million people are infected with HIV with ca. 6,000 new infections each day. Therefore, a vaccine is still desperately needed.
By using new scientific knowledge, a new large-scale collaboration of scientists from various disciplines hopes to increase the chances to develop an effective vaccine against AIDS. BPRC is part of this consortium. Formed by 39 partners from 16 countries, this partnership, European HIV Vaccine Alliance (EHVA) focuses on the identification and characterization of novel vaccine candidates for AIDS.
Moreover, this consortium has the aim to determine the efficacy of vaccine candidates at an early stage, in order to accelerate the development of an effective vaccine. This research is funded by the European Union for the next five years.